Search

Your search keyword '"Bagnara D"' showing total 2 results
Start Over Author "Bagnara D" Publisher ferrata storti foundation
2 results on '"Bagnara D"'

1. A reversible carnitine palmitoyltransferase (CPT1) inhibitor offsets the proliferation of chronic lymphocytic leukemia cells.

Author

Gugiatti E, Tenca C, Ravera S, Fabbi M, Ghiotto F, Mazzarello AN, Bagnara D, Reverberi D, Zarcone D, Cutrona G, Ibatici A, Ciccone E, Darzynkiewicz Z, Fais F, and Bruno S

Subjects
A549 Cells, Carnitine O-Palmitoyltransferase genetics, Carnitine O-Palmitoyltransferase metabolism, HCT116 Cells, Humans, MCF-7 Cells, Neoplasm Proteins genetics, Neoplasm Proteins metabolism, PC-3 Cells, Carnitine O-Palmitoyltransferase antagonists & inhibitors, Cell Proliferation drug effects, Enzyme Inhibitors pharmacology, Leukemia, Lymphocytic, Chronic, B-Cell enzymology, Leukemia, Lymphocytic, Chronic, B-Cell genetics, Leukemia, Lymphocytic, Chronic, B-Cell pathology, Neoplasm Proteins antagonists & inhibitors
Published
2018
Full Text
View/download PDF

2. Adoptive immunotherapy mediated by ex vivo expanded natural killer T cells against CD1d-expressing lymphoid neoplasms.

Author

Bagnara D, Ibatici A, Corselli M, Sessarego N, Tenca C, De Santanna A, Mazzarello A, Daga A, Corvò R, De Rossi G, Frassoni F, Ciccone E, and Fais F

Subjects
Animals, Hematologic Neoplasms immunology, Humans, Immune System, Immunohistochemistry methods, Immunotherapy methods, Mice, Mice, Inbred NOD, Mice, SCID, Natural Killer T-Cells metabolism, Neoplasm Transplantation, Antigens, CD1d metabolism, Hematologic Neoplasms therapy, Immunotherapy, Adoptive methods, Killer Cells, Natural metabolism, Natural Killer T-Cells immunology, T-Lymphocytes pathology
Abstract

Background: CD1d is a monomorphic antigen presentation molecule expressed in several hematologic malignancies. Alpha-galactosylceramide (alpha-GalCer) is a glycolipid that can be presented to cytotoxic CD1d-restricted T cells. These reagents represent a potentially powerful tool for cell mediated immunotherapy., Design and Methods: We set up an experimental model to evaluate the use of adoptively transferred cytotoxic CD1d-restricted T cells and alpha-GalCer in the treatment of mice engrafted with CD1d(+) lymphoid neoplastic cells. To this end the C1R cell line was transfected with CD1c or CD1d molecules. In addition, upon retroviral infection firefly luciferase was expressed on C1R transfected cell lines allowing the evaluation of tumor growth in xenografted immunodeficient NOD/SCID mice., Results: The C1R-CD1d cell line was highly susceptible to specific CD1d-restricted T cell cytotoxicity in the presence alpha-GalCer in vitro. After adoptive transfer of CD1d-restricted T cells and alpha-GalCer to mice engrafted with both C1R-CD1c and C1R-CD1d, a reduction in tumor growth was observed only in CD1d(+) masses. In addition, CD1d-restricted T-cell treatment plus alpha-GalCer eradicated small C1R-CD1d(+) nodules. Immunohistochemical analysis revealed that infiltrating NKT cells were mainly observed in CD1d nodules., Conclusions: Our results indicate that ex vivo expanded cytotoxic CD1d-restricted T cells and alpha-GalCer may represent a new immunotherapeutic tool for treatment of CD1d(+) hematologic malignancies.

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results